Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

440
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
440
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

820
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
820
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

25
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
25

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease.

Nature aging·2026
Same author

Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical Study.

Movement disorders : official journal of the Movement Disorder Society·2024
Same author

A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2023
Same author

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.

Movement disorders : official journal of the Movement Disorder Society·2021
Same author

On-Demand Therapy for OFF Episodes in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2021

Related Experiment Video

Updated: Oct 12, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.7K

Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity.

Milton H Werner1, C Warren Olanow2,3

  • 1Inhibikase Therapeutics, Inc., Atlanta, Georgia, USA.

Movement Disorders : Official Journal of the Movement Disorder Society
|November 24, 2021
PubMed
Summary

Abelson tyrosine kinase (c-Abl) activation drives Parkinson's disease pathology by promoting alpha-synuclein accumulation and neurodegeneration. Novel c-Abl inhibitors show promise for disease modification in Parkinson's disease.

Keywords:
Abelson tyrosine kinaseParkinson's diseasedisease-modification

More Related Videos

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.7K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K

Related Experiment Videos

Last Updated: Oct 12, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.7K
Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.7K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K

Area of Science:

  • Neuroscience
  • Neurodegenerative Diseases
  • Molecular Biology

Background:

  • Parkinson's disease (PD) is a widespread neurodegenerative disorder affecting multiple neuronal systems.
  • Alpha-synuclein misfolding and aggregation are central to PD pathogenesis.
  • Abelson tyrosine kinase (c-Abl) activation is implicated in PD progression.

Purpose of the Study:

  • To review the role of c-Abl in Parkinson's disease.
  • To explore the potential of c-Abl inhibitors as disease-modifying therapies for PD.

Main Methods:

  • Review of animal models of PD and post-mortem human studies.
  • Analysis of alpha-synuclein phosphorylation and c-Abl activity.
  • Evaluation of c-Abl inhibitors in preclinical and clinical settings.

Main Results:

  • Internalized alpha-synuclein activates c-Abl, leading to alpha-synuclein phosphorylation and neurodegeneration.
  • c-Abl inactivates parkin, impairing mitochondrial function and promoting neurodegeneration.
  • Elevated tyrosine phosphorylated alpha-synuclein observed in PD patients indicates c-Abl activation.

Conclusions:

  • c-Abl plays a critical role in the initiation and progression of PD.
  • Novel brain-penetrant c-Abl inhibitors demonstrate therapeutic potential in PD models.
  • Further clinical development of c-Abl inhibitors is warranted for Parkinson's disease treatment.